|
Heart Diseases
|
0.300 |
Biomarker
|
group |
CTD_human |
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.
|
26237429 |
2015 |
|
Congenital musculoskeletal anomalies
|
0.300 |
Biomarker
|
group |
CTD_human |
Contribution of retinoic acid receptor gamma to retinoid-induced craniofacial and axial defects.
|
9142499 |
1997 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Collectively, our results defined RARγ as tumor suppressor in colorectal cancer that acts by restricting oncogenic signaling by the Hippo-Yap pathway, with potential implications for new approaches to colorectal cancer therapy.
|
27325643 |
2016 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Modulation of the RARα/β to RARγ expression in mammary glands of normal mice, oncomice, and human mammary cell lines through the alteration of RAR-target gene expression affected cell proliferation, survival and tumor growth.
|
22920668 |
2012 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
We, firstly, examined primary NB tumor tissue for a correlation between endogenous RAR gamma expression and clinical stage of the tumor and secondly, the effects of exogenous over-expression of the RAR gamma gene on a human NB tumor cell line.
|
7630632 |
1995 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
We recently demonstrated that retinoic acid receptor-γ (RARγ) is overexpressed and acts as a tumor promoter in hepatocellular carcinoma (HCC).
|
28336971 |
2017 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Differentiation of T1338 was induced by RARα and RARγ isotype-selective retinoids, associated with down-regulation of Sox2, and the failure to induce orthotopic tumors in the brains of SCID mice.
|
25171789 |
2014 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
In addition, some genes were up-regulated, including matrix metalloproteinse 2(MMP-2), MMP-16(MT3-MMP), SKY, CD9 and semaphorin V. A number of genes were down-regulated, including neuroendocrine-dlg (NE-dlg), retinoic acid receptor gamma and tumor suppressor DCC colorectal.
|
12174360 |
2002 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Histologic analysis demonstrated that RARγ agonist treatment inhibited cell proliferation activity and stimulated encapsulation of the tumor.
|
31808569 |
2019 |
|
Adenocarcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Retinoic acid receptor-alpha messenger RNA expression is increased and retinoic acid receptor-gamma expression is decreased in Barrett's intestinal metaplasia, dysplasia, adenocarcinoma sequence.
|
11231454 |
2001 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Acacetin induces cancer cell apoptosis through antagonizing the non-genomic effect of RARγ on AKT and p53.
|
28336971 |
2017 |
|
B-Cell Lymphomas
|
0.010 |
Biomarker
|
group |
BEFREE |
Here we investigated the novel BH3 domain mimetic, JY-1-106, which antagonizes the anti-apoptotic BCL-2 family members B-cell lymphoma-extra large (BCL-xL) and myeloid cell leukemia-1 (MCL-1) alone and in combination with retinoids including atRA, AM580 (RARα agonist), and SR11253 (RARγ antagonist).
|
25088254 |
2014 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Acacetin induces cancer cell apoptosis through antagonizing the non-genomic effect of RARγ on AKT and p53.
|
28336971 |
2017 |
|
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways.
|
31374203 |
2019 |
|
Vital capacity
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis.
|
22920668 |
2012 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Here, we identify the nuclear receptor RARγ as a regulator of the Hippo-Yap pathway in colorectal tumorigenesis and metastasis.
|
27325643 |
2016 |
|
Neoplasm Metastasis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
RARγ is downregulated in human colorectal cancer tissues, where its expression correlates inversely with tumor size, TNM stage, and distant metastasis.
|
27325643 |
2016 |
|
Intestinal metaplasia
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Retinoic acid receptor-alpha messenger RNA expression is increased and retinoic acid receptor-gamma expression is decreased in Barrett's intestinal metaplasia, dysplasia, adenocarcinoma sequence.
|
11231454 |
2001 |
|
Cardiotoxicity
|
0.400 |
Biomarker
|
disease |
CTD_human |
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.
|
26237429 |
2015 |
|
Cardiotoxicity
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.
|
26237429 |
2015 |
|
Malignant neoplasm of breast
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Pre-clinical observation highlighted that triple negative (estrogen receptor/progesterone receptor/human epidermal growth factor receptor)-breast cancer cells displayed resistance to retinoids due to the RARγ high expression profile.
|
29849791 |
2018 |
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
Potential role for retinoic acid receptor-gamma in the inhibition of breast cancer cells by selective retinoids and interferons.
|
8603404 |
1996 |
|
Malignant neoplasm of breast
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
The functional consequence of the interplay between c-Myc oncogene expression and the RARγ to RARα/β balance suggests that prevalence of RARγ over-RARα/β expression levels in breast cancer accompanied by c-Myc amplification or over-expression in breast cancer should be predictive of response to treatment with RARα-isotype-specific agonists and warrant monitoring during clinical trials.
|
22920668 |
2012 |
|
Malignant neoplasm of breast
|
0.330 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|